Published in final edited form as:

J Control Release. 2015 December 10; 219: 141–154. doi:10.1016/j.jconrel.2015.08.060.

Drug Delivery, Cell-based Therapies, and Tissue Engineering Approaches for Spinal Cord Injury

Shushi Kabu¹, Yue Gao¹, Brian K. Kwon², and Vinod Labhasetwar^{1,*}

¹Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

²Department of Orthopaedics, University of British Columbia, Vancouver, BC, Canada V5Z 1M9

Abstract

Spinal cord injury (SCI) results in devastating neurological and pathological consequences, causing major dysfunction to the motor, sensory and autonomic systems. The primary traumatic injury to the spinal cord triggers a cascade of acute and chronic degenerative events, leading to further secondary injury. Many therapeutic strategies have been developed to potentially intervene in these progressive neurodegenerative events and minimize secondary damage to the spinal cord. Additionally, significant efforts have been directed towards regenerative therapies that may facilitate neuronal repair and establish connectivity across the injury site. Despite the promise that these approaches have shown in preclinical animal models of SCI, challenges with respect to successful clinical translation still remain. The factors that could have contributed to failure include important biologic and physiologic differences between the preclinical models and the human condition, study designs that do not mirror clinical reality, discrepancies in dosing and the timing of therapeutic interventions, and dose-limiting toxicity. With a better understanding of the pathobiology of events following acute SCI, developing integrated approaches aimed at preventing secondary damage and also facilitating neurodegenerative recovery is possible, and hopefully will lead to effective treatments for this devastating injury. The focus of this review is to highlight the progress that has been made in drug therapies and delivery systems, and also cell-based and tissue engineering approaches for SCI.

Graphical Abstract

* Author for correspondence: Vinod Labhasetwar, Ph.D., Department of Biomedical Engineering/ND-20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, Tel: 216/445-9364; Fax 216/444-9198, labhasv@ccf.org. SK and YG contributed equally

Conflict of Interest: Dr. Vinod Labhasetwar is a Co-Founder and Chief Scientific Officer of ProTransit Nanotherapy (<http://www.protransitnanotherapy.com/>), a start-up company established based on the technologies developed at the University of Nebraska Medical Center (Omaha, NE), his former institution and Cleveland Clinic, his current institution. If the technology described in this review from his laboratory is successful, the author and both the institutions may benefit. The conflict of interest is managed by the Conflict of Interest Committee of Cleveland Clinic in accordance with its conflict of interest policies.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Drug Therapy; Polymers; Scaffold; Growth Factors; CNS Injury; Inflammation; Gene Therapy

1. Introduction

According to the 2013 report from Christopher & Dana Reeve Foundation, more than a million people in the U.S., ~0.4% of the U.S. population, are living with paralysis due to spinal cord injury (SCI) (1), with about 12,000 new cases added each year (2), and it is estimated to cost \$40.5 billion annually to the healthcare industry. Disability due to SCI is a major global issue, affecting both young and elderly populations (2). In addition, military conflicts have contributed to a significant rise of combat-related spinal fractures and spinal cord injuries, imparting substantial disability in affected populations (3).

1.1. Pathology of SCI

The pathophysiology of traumatic SCI involves primary and secondary damage. The primary injury is considered to be disruption of neural tissue as the immediate result of the blunt, non-penetrating mechanical forces applied at high velocity to the spinal cord as the surrounding bony/ligamentous spinal column fails. Primary mechanical trauma exerts distraction, compression, and shear forces on the spinal cord (4, 5), and can cause damage not only to the central nervous system (CNS) but also the peripheral nervous system (6). Vascular, cellular and axonal damage occurs almost instantaneously and continues to spread from the injury epicenter both radially and axially. Edema of the spinal cord occurs in parallel and may cause further disruption to spinal cord blood flow, exacerbating ischemia (7). The damaged and necrotic cells at the site of primary injury contribute to the secondary injury cascade which has an acute, intermediate and chronic phase, and spreads with time both caudal and cranial to the primary lesion (8) (Figure. 1). The secondary injury eventually leads to the formation of a glial scar (9, 10) which can further impede axonal regeneration (11). Wallerian degeneration, a post-traumatic axonal degeneration distal to the site of disruption continues over a few days to months after SCI (12).

1.2. Therapeutic and regenerative strategies for treatment of spinal cord injury

Following surgical interventions that include early spinal decompression and stabilization surgery (13), current treatments used for SCI can be categorized mainly as neuroprotective or neuroregenerative in nature. Neuroprotective therapies focus on impeding or preventing further progression of the secondary injury, whereas neuroregenerative therapies lay

emphasis on recovering the lost or impaired functionality by repairing the broken neuronal circuitry of the spinal cord (14, 15). Preclinical research has revealed that many elements of the secondary injury cascade occur over a prolonged period of time post-injury, providing an opportunity for neuroprotective exogenous treatments to be effective if applied within this time period (10, 16). This review covers drug based therapies, both neuroprotective and neuroregenerative in nature, that target a single and/or multiple events in this timely cascade of neurodegenerative events, as shown in Figure 1. However, once the window for therapeutic intervention to prevent secondary injury cascades has passed, the focus turns towards regeneration of the injured spinal cord. Given the enormous complexity of the biological issues facing SCI repair, McDonald & Sadowsky (6) suggested a hierarchy of interventions: (i) limiting secondary damage by surgery, (ii) re-myelination of axons or compensating for it, (iii) eliminating or ablating inhibitory factors, (iv) delivering neurotrophins or growth factors to enhance neuronal growth and axonal regeneration, (v) guiding axons to establish correct connections, (vi) creating bridges by biomaterials and cell grafts to connect nerve fibers, and (vii) removing injured or dead cells. Many of the treatment options and therapies described in the review target one or the other mechanism as described above. These options depend upon the state of the patient. Early interventions following primary injury are aimed at preventing cascades of secondary degeneration, particularly drug and neuroprotective therapies, whereas at a chronic stage, it is primarily regenerative therapy such as cell-based therapies, tissue engineering, either through remyelination and/or axonal sprouting to establish neuronal connectivity and achieve functional recovery.

2. Drugs and Drug Delivery Systems

Many different drug therapies have been tested to prevent the spread of secondary injury and facilitate regeneration. Therapeutic approaches are targeted at either single and/or multiple pathways in the cascade of degenerative events, as described in Figure 1. One of the important challenges in drug therapy is to achieve an effective dose and maintain levels for sufficient time period at the lesion site to achieve therapeutic effect. Systemic administration is the obvious choice for delivering agents, provided that they can cross the blood-spinal cord barrier (BSCB) (although this may also be disrupted early after injury). Oral administration for systemic delivery is also possible and obviously more convenient for the patient, although limited gut absorption and subsequent bioavailability at the impact site may influence the therapeutic effect (17). Systemically delivering comparable doses to humans as are effective in animal models may be limited by tolerance in humans and could be a limiting factor in translation of effective therapies (18, 19). Therefore, various drugs and biomolecules have been tested via epidural, intrathecal or intraspinal routes. Administration to the epidural space might provide more targeted therapy than systemic delivery, but requires that therapeutic agents are able to cross the dura, pia and arachnoid meninges that envelop the spinal cord (20). The intrathecal route also aims at better specificity by delivering the agents directly to the spinal cord. This can be achieved via continuous infusion through an indwelling intrathecal catheter, or by repeated lumbar injections. Accessing the intrathecal space in this manner does pose a risk for introducing infection and direct injury to the neural elements (21).

2.1. Therapeutic Strategies

Drug therapies focus on impeding or preventing further progression of the secondary injury by alleviating key injury mechanisms such as apoptosis, oxidative stress or inflammation (22). A few of the therapies that have been tested include erythropoietin (EPO), NSAIDs, minocycline, riluzole, estrogen, and atorvastatin (23). In general, these treatments have shown modest yet promising improvements in preclinical animal models specifically in terms of motor recovery and tissue sparing.

2.1.1. Immunomodulatory therapies—The inflammatory response to SCI is extremely complex, and its beneficial and detrimental roles in the recovery process remains incompletely understood (24). Clinically, the glucocorticoid **methylprednisolone (MP)** was thought to render neuroprotection by suppressing secondary inflammation and lipid peroxidation when administered at high doses within 8 hours of injury (25). Controversy around its real neurologic efficacy has plagued the use of MP for the last 15 years, and many have abandoned its use for fear of severe complications including pneumonia, sepsis, and death (26). In animal models of SCI, several other drugs that are already FDA-approved for other human diseases have shown promise as neuroprotective agents, potentially by modulating the inflammatory response. These include **Rolipram**, an inhibitor of phosphodiesterase type 4 proteins, **FTY720**, a sphingosine receptor modulator for relapsing multiple sclerosis, **Imatinib**, clinically used for treating leukemias and gastrointestinal stromal tumors and **Atorvastatin (Lipitor)**, for lowering cholesterol. Investigators have noted these drugs to be associated with a reduction in inflammatory cells, inhibition of apoptosis, increased tissue sparing and enhanced locomotor recovery in animal SCI studies (27–29).

Several groups have explored either single and/or combinatorial approaches with **Rolipram** and other drugs to synergistically target subsequent degenerative pathways, while exerting neuroprotection and functional recovery (30, 31). Anti-inflammatory cytokines such as **Interleukin-10 (IL-10)** have shown potential for treatment in SCI models (32) with efficacy in improving functional recovery and tissue preservation while reducing neuropathic pain and inflammatory cytokine levels (33, 34). Endogenous growth factor **EPO** has shown significant attenuation of inflammation and apoptosis, maintenance of microvasculature and tissue integrity, and improved motor activity when administered within 24 h after SCI (35, 36). EPO demonstrates a safe pharmacological profile causing decreased leucocyte infiltration and inhibiting lipid peroxidation by-products while also exhibiting hematopoietic activity which may increase the risk of thrombosis, but non-hematopoietic EPO analogues as tissue protective cytokine have been investigated (35, 37). The glycolytic enzyme **chondroitinase ABC (ChABC)** has been investigated for its immunomodulatory benefits after it showed significant restoration of neuronal regeneration and plasticity by directly attacking the CSPG inhibitory activity in the glial scar in both small and large animal populations (38, 39). ChABC gene therapy significantly reduced the secondary injury and improved spinal conduction through modulation of macrophage phenotype to favor the pro-repair M2 macrophages (40).

2.1.2 Targeting axonal growth—Injured CNS myelin contains growth inhibitory molecules that impede the regeneration of injured axons (16). Some level of spontaneous re-growth has been shown to occur, but this development pattern is inconsistent due to lack of pathway guidance or molecular cues causing dysfunctional axon growth (12). One of the best-studied approaches to this problem is the neutralization of Nogo-A, a myelin associated protein, via anti-Nogo-A specific antibodies. This has been shown to enhance sprouting and regeneration of lesioned axons and unlesioned fiber tracts with substantial improvements in functional recovery in rodent and monkey SCI models (41–43). Another promising approach for encouraging axonal growth is to target downstream intracellular signaling pathways within the growth cone such as the Rho/Rac pathway. Rho antagonists such as C3-exoenzyme, fasudil, Y-27532, and ibuprofen have been found to promote improved locomotor outcome in animal models of SCI, and some of these approaches have been translated into human clinical trials. Exogenous delivery of neurotrophins has also shown potential in modulating sensorimotor physiology and plasticity of spinal cord circuits after SCI by influencing cellular processes, but most of the current therapies focus on using them in combination with other cellular transplantation strategies, as discussed in Sections 3 & 4 (44, 45).

2.1.3. Targeting apoptosis/necrosis—A few groups have explored the use of calpain inhibitors in treating SCI, based on the role it plays in the cause and progression of neuronal injury through cytoskeletal protein degradation and programmed cell death, and have shown increased tissue preservation and improved motor recovery in SCI models (46–48). Das et al. showed that pre-treatment of motoneurons with calpeptin prevented apoptosis and maintained their functionality when exposed to glutamate induced excitotoxic environment, thus providing neuroprotection in-vitro (46). Combining calpeptin with MP reported reduction in DNA fragmentation and secondary inflammation in a contusion SCI model; however, no locomotor improvements or pathological markers were investigated, which makes it difficult to analyze the mechanisms which may be at play while the treatment worked synergistically (47). Targeting and modulating signaling pathways, specifically the c-Jun-N-terminal kinase (JNK) pathway involved in apoptosis (49), has shown both neuroprotection and pain attenuation (50). D-JNKI1, a cell permeable peptide inhibitor of JNK, has shown prevention of caspase3 activation, increased locomotor recovery and white matter sparing when administered 6h post-SCI in mice (51).

2.1.4. Targeting ischemia/hypoxia—Yacoub et al. used Oxycyte, an intravenous injectable perfluorocarbon, to relieve the long-lasting ischemia and hypoxia resulting post-SCI by improving the tissue oxygenation in a contusion model, and reported decreased lesion sizes with improved locomotor function and white matter preservation (52). Although they focused on the use of Oxycyte as a monotherapy, the authors proposed a combinative therapy with other immunomodulatory compounds that are already FDA approved, such as FTY 720 (27).

2.1.5. Targeting excessive iron accumulation—Damage to the blood vasculature post-SCI causes excess iron to accumulate in the spinal cord which causes iron-induced oxidative stress. Multiple groups have sought to demonstrate the involvement of iron in the

progression of the secondary injury using iron chelation therapies, and have shown locomotor improvements and reduced pathologies (53–55). However oral administration of iron therapies such as chelating agents (e.g. quercitin, deferoxamine and ceruloplasmin) must be preceded with caution as it can induce negative side effects such as systemic anemia (56).

2.1.6. Targeting oxidative stress—Excessive formation of reactive oxygen species (ROS) is a well characterized pathological process occurring during the acute and intermediate phases of secondary SCI, causing damage to cell membrane lipids, proteins and DNA resulting in neuronal cell apoptosis and death (57, 58). Studies have been conducted to mitigate acrolein mediated oxidative damage and neuronal injury by use of acrolein scavengers, most notably hydralazine (59). Park et al. showed that daily intraperitoneal injections of **hydralazine** were effective in reducing acrolein levels, motor deficits and neuropathic pain in contusive SCI model (60). Hydralazine has a half-life period of a few hours (61) and this can be a limiting factor for experimental and clinical studies. **Melatonin**, a hormone responsible for regulating circadian rhythms, has been shown to exert a scavenging effect against hydroxyl and peroxy radicals mediated oxidative damage (62). Apart from a decrease in lipid peroxidation, studies in contusion and compression SCI models have shown melatonin to preserve neuronal, axonal and BSCB architecture and enhance functional recovery (63–66). Another recent study has tested the efficacy of combining melatonin with exercise-based neurorehabilitation and successfully reported decrease in nitric oxide levels as well as an increase in motor neurons (67). High doses of antioxidants, **Vitamins C & E** (100 mg/kg/day), in an SCI model have shown to lessen the inflammatory response, but no improvements in neurological performance were observed (68).

2.1.6.1 Antioxidant enzymes: In our studies, we are exploring superoxide dismutase (SOD)- and catalase (CAT)-loaded antioxidant nanoparticles to inhibit the spread of secondary injury cascades. Normal brain and spinal tissue contain high levels of endogenous antioxidants to counteract the ROS (69) that are continuously produced due to the metabolism of excitatory amino acids and neurotransmitters (70, 71). However their levels are not sufficient to neutralize excessive ROS formed post SCI. Initially there is a transient increase in antioxidant activities, particularly of SOD and CAT post-SCI, but due to their rapid consumption and the downregulation of their genes, neuronal cells are unable to maintain the redox balance, a condition leading to oxidative stress (72). Wang et al. (73) have shown decreasing SOD and CAT activities in the injured spinal cord with time, reaching undetectable levels by 14 d post injury. Their study also reported a concomitant increase in stress proteins, known to trigger inflammation, signifying the role of SOD and CAT in neuroprotection against oxidative stress. The high levels of unsaturated lipids and fatty acids present in neuronal cells make them highly susceptible to oxidative damage (74).

Various pharmacodynamic factors impede the straightforward use of native forms of SOD or CAT in SCI because **a)** their molecular weights are well below the renal glomerular filtration cutoff, resulting in their rapid clearance from systemic circulation ($t_{1/2}$ of SOD in rats = 4–8 min, CAT = 8–10 min); **b)** they are negatively charged at physiological pH and

therefore do not readily cross the cell membranes (75); and c) neurons and astrocytes do not appear to take up the native enzyme under normal conditions and hence cannot neutralize the ROS formed intracellularly (76). Different alternatives have been investigated to address these issues, e.g., PEGylation and lecithinization to improve their circulation half-life (77); however, there are limitations to these modifications, e.g., PEGylated SOD (PEG-SOD) increases the enzyme's stability in the circulation from 6 min to 36 h, but it limits the permeability of SOD across cerebral cell membranes and SOD's uptake by neuronal cells (78). Instability of liposomes *in vivo* (half-life ~4.2 hr) limits the duration of SOD activity and efficacy (79, 80). To address these issues, we have designed a sustained nano-SOD/CAT, consisting of forms of the antioxidant enzymes SOD and CAT encapsulated in biodegradable nanoparticles (NPs). In our published studies, using a hydrogen peroxide-induced oxidative stress model, we have demonstrated complete neuroprotection with SOD-NPs, whereas SOD and PEG-SOD were ineffective (81) (Figure 2). Recently, we demonstrated a similar protective effect of CAT-NPs in human neurons (82) and astrocytes; the efficacy of encapsulated enzymes has been attributed to their efficient NP-mediated intracellular delivery and sustained protective effect (Figure 3).

2.1.7. Nanoparticle-mediated drug delivery—In addition to our study to deliver antioxidant enzymes using NPs as described above, several other groups have explored NPs as a drug delivery system to sustain drug effect at the impact site. The small size of NPs allows them to cross cell membranes or BSCB, thus greatly extending the bioavailability of drugs in the lesion site (83). NP based delivery of MP has been explored by various groups to improve the drug efficacy while neutralizing some of the detrimental side effects that are associated with its systemic high doses. PLGA-NPs and carboxymethylchitosan/polyamidoamine dendrimers loaded with MP have shown significant reduction in the lesion size, improved behavioral outcomes, suppression of microglial and astrocytic responses and improved axon regeneration in hemisection SCI models (84, 85). Systemic administration of ferulic acid (FA)- glycol chitosan (GC) (FA-GC) NPs was reported to cause improvements in locomotion, axonal and myelin protection, attributed to the neuroprotective properties of FA and GC which extend anti-oxidative effects to prevent inflammation and excitotoxicity (86). Administration of small molecule inhibitors such as Chicago sky blue, a macrophage migration inhibitory factor, encapsulated in NPs increased white matter and blood vessel integrity post-SCI (87), but demonstrated activation of both pro- and anti-inflammatory signals which could be ascribed to dynamic changes in macrophage phenotypes while still being reparative in nature (88). Another pharmacological approach modulated the activated microglia/macrophage response in the subacute phase of inflammation by using minocycline loaded polymeric polycaprolactone NPs (89). These authors observed reduced proliferation and altered morphology from activated to resting phase in the microglia/macrophage environment, due to the antioxidant and neuroprotective effect of minocycline (90). PEG functionalized silica NPs have been used by Cho et al. (91) in crush/contusion SCI and the results show blockage of the resulting lipid peroxidation and ROS upregulation, recovery of somatosensory evoked potential conduction and maintenance of membrane structure and integrity. Another study by Wang et al. used an intraspinal injection of GDNF loaded PLGA NPs in a contusion SCI model and saw an increase in neuronal survival and locomotor improvements (92).

2.1.8. Hydrogels-mediated drug delivery—Hydrogels are three-dimensional nanostructured networks of hydrophilic polymers with superior similarity to native extracellular matrix (ECM). Due to their tunable mechanical property and degradation profile, hydrogels are used as excellent scaffolds for both drug release and cell support with good biocompatibility (Cell-based therapy utilizing hydrogels is discussed later in Section 4.1). With proper *in situ* gelation, hydrogels can be precisely injected to fill up the SCI lesion by exact geometrical re-shaping, which avoids more invasive surgeries that potentially exaggerate established injury. Sustained and localized release of MP was achieved by encapsulating MP into biodegradable nanoparticles, which were then embedded in an agarose hydrogel implanted into contusion injury, and significantly reduced lesion volume 7 days after injury (93). Chondroitinase ABC (ChABC) as a promising annihilator for glial scars has been incorporated in various hydrogels for sustained and controlled release, which has generated encouraging results (94, 95). Multiple studies have utilized engineered hydrogels to release neurotrophins and growth factors directly into the SCI lesion and demonstrated supplementary exogenous neurotrophins such as NT-3, VEGF, GDNF, NGF, and BDNF could facilitate locomotive recovery in SCI (96, 97). Compared with commonly used methods such as direct injection, systemic administration and intrathecal infusion, hydrogels are able to provide a sustained and tunable release of loaded growth factors (98, 99). Hydrogels are promising carriers for controlled drug release, yet investigation about their long-term safety and biocompatibility after implantation is needed for further clinical application.

2.2. Clinical trials based on drug therapies

Clinical trials for SCI using therapeutics have been underway for a number of years, although the neurological efficacy of these agents is still undetermined. A brief summary of the current clinical trials using drug therapies is provided in Table 1 below. A few of the drugs that have been or are currently being assessed include:

- **Minocycline:** Minocycline is a long-acting, broad-spectrum antibiotic that works through immunomodulation of microglia proliferation, reduced excitotoxicity and mitochondrial stabilization resulting in reduced apoptosis and neutralization of oxygen radicals and nitric oxide synthase inhibition (100). Pre-clinical studies have shown a neuroprotective effect in acute SCI and reduction in neuropathic pain (101, 102). A recently concluded Phase II clinical trial (NCT00559494) was able to determine safe and adequate dosage in acute SCI. The trial was not powered to establish efficacy, but there was some suggestion of a benefit to individuals with incomplete cervical SCI (100). A Phase III study is currently underway (NCT01828203), aiming to evaluate the efficacy of minocycline in improving neurological and functional outcome after acute traumatic non-penetrating cervical SCI.
- **Riluzole:** Riluzole is a benzothiazole anticonvulsant that works through blockage of the sodium channels, which prevents increase of intracellular sodium and calcium concentrations, thereby inhibiting excitotoxicity (103). Pre-clinical studies demonstrated a neuroprotective effect in acute SCI, reversed neuropathic pain and reduced spastic muscle activity (104, 105). A recently concluded Phase IIa clinical

trial (NCT00876889) was able to determine the safety and pharmacokinetic profile of riluzole in SCI patients, which has helped in the development of a definitive efficacy study (103, 106). A Phase II and III trial (NCT01597518) is currently underway to evaluate the effect of riluzole on neurological, functional and sensory recovery on SCI patients.

- **Cethrin:** The active component of Cethrin is a cell and BSCB permeable synthetic variant of C3 transferase, which blocks the Rho signaling pathway. This is thought to inhibit apoptosis and promote axonal regeneration (107, 108). Pre-clinical studies in acute-SCI have shown diffusion of the BA-210 into the lesion site, inactivation of Rho in a dose-dependent manner, improved tissue sparing and functional recovery (108). Cethrin is administered within a fibrin glue that is applied directly to the dura over the injury site at the time of decompressive surgery. A Phase I/II multi-center trial of Cethrin has been completed and reported improvements in motor function in a dose-dependent manner (107).
- **Erythropoietin:** EPO, a glycoprotein hormone, has been used in numerous preclinical animal studies and has shown promising neurological recovery and tissue sparing (35, 109, 110). A recently concluded pilot study (NCT00561067) assessed the efficacy of EPO and MP in acute SCI patients. This trial was too small to realistically assess efficacy of the EPO, but it appears to be safe and well-tolerated (111).
- **Anti-Nogo-A antibody:** Nogo-A is a myelin protein in the CNS that inhibits neurite growth (112). In arguably the most extensively studied approach to promoting CNS regeneration after SCI, it was with great expectations that a clinical trial evaluating anti-Nogo antibodies was launched. This trial (a Phase I clinical trial, Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrathecally Administered ATI355 in Patients With Acute SCI (NCT00406016)) was completed a number of years ago and the data has not yet been published from it (112).
- **Dalfampridine:** The tablet formulation of dalfampridine contains the active agent 4-Aminopyridine, a potassium channel blocker, and is also known by Fampridine-SR which stands for sustained release of dalfampridine. Pre-clinical studies have shown increased conduction in demyelinated axons in rats and modest tolerance of the drug with no significant differences between SCI and placebo groups in two Phase III clinical trials (113, 114). A Phase II clinical trial (NCT01621113) is currently underway to determine the safety, tolerance and efficacy of dalfampridine when used in combination with locomotor training in chronic, motor incomplete SCI patients vs. placebo controls.

3. Cell-based Therapies

The loss of neuronal tissue and the establishment of a cystic cavity at the injury site has made cell transplantation an attractive strategy for SCI. Over the last several decades, multiple lineages of cells have been tested, based on their specific functional potentials in the context of spinal cord regeneration. Cell-based therapeutic strategy has become the most important part of translational medicine and clinical trials for SCI. Grafting of somatic cells

and tissues such as olfactory-ensheathing cells (OECs), Schwann cells, fetal tissues, peripheral nerves have made the SCI microenvironment more favorable for neural regeneration (115). On the other hand, neural progenitor/stem cells, embryonic stem cells, induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), fibroblast-derived stem cells, etc. are all exploited for their pluripotent differentiation ability to replace neuronal lineage cells, enhance axonal regeneration and restore inter-neuron communications (116). Stem cell-based therapy is promising, yet potential side effects and safety concerns do exist, such as ethical issues, immunological rejection, and tumor formation (117). Cell transplantation can also act as a vehicle for gene delivery. Genetically modified Schwann cells and others have been attempted for SCI to promote nerve regeneration (118). Moreover, genetically engineered MSCs have also been used to deliver many factors such as neurotrophic factors, receptor tyrosine kinases, and HGF to promote survival of themselves and the regeneration of damaged neurons (119).

3.1. Neural stem/progenitor cells and oligodendrocyte progenitor cells

Neural stem/progenitor cells (NS/PCs) refer to the multipotent cells that give rise to other cells of the nervous system (120). Recently NS/PCs have been identified in the spinal cord along the central canal down to the filum terminale (FT), which originally regarded as clinically useless but now has been found to be a source of NS/PCs in both rats and human (121). NS/PCs can be expanded in a neural sphere culture system, and differentiate when adhesive substrate is provided and mitogens removed. NS/PCs derived from spinal cord give rise to a consistent “neuron: glia” ratio of 3:1 (120, 122). NS/PCs are less tumorigenic than embryonic stem cells (ESCs) and have been safely used to treat patients with stroke, Parkinson’s disease, and cerebral palsy (123). To further reduce this risk, a more downstream progenitor, oligodendrocyte progenitor cells (OPCs) are used instead of NS/PCs for transplantation. OPCs could be obtained from human fetal NS/PCs for large scale production to meet the clinical demand (122).

3.2. Olfactory ensheathing cells and olfactory mucosa cells

Olfactory ensheathing cells (OECs) have been tested for SCI (124). During normal cell turnover, new olfactory receptor neurons (ORNs) are able to extend axons to re-enter the olfactory bulb and re-synapse with second-order neurons in the glomerular layer. This process of axonal regeneration from the peripheral to central nervous system is facilitated by OECs. Recently, researchers in Poland have described their experience using cells taken from the olfactory bulb and olfactory mucosa in human SCI patients (125). In semi-transected cervical spinal cord, injected OECs induced elongating axons into the denervated caudal host tract (126). Six patients received autologous OEC transplantation in a Phase I clinical trial, of whom three patients showed signs of improvement of SCI, and two improved from ASIA-A to -C and -B (127). To overcome the difficulty to obtain OECs, olfactory mucosa cells (OMCs) were tested and have promoted axonal outgrowth (128, 129). However, OMC transplantation performed in Portugal resulted in formation of tumor-like structure, which could have been due to improper purification of cells (130).

3.3. Bone marrow stromal cells/mesenchymal stem cells

Bone marrow stromal cells and mesenchymal stem cells (MSCs) are essentially from the same group of stem/progenitor cells, but differ in their cell procuring processes. MSCs can be conveniently obtained from bone marrow, blood, adipose and dental tissues. MSCs are able to differentiate into essentially all non-hematopoietic lineages, thus holding great clinical potential (131). Animal studies with SCI have shown that transplanted MSCs survived in the spinal cord, migrated into the host tissue and led to axonal regeneration and motor function recovery (131). MSCs have innate neuroprotective properties, as they create a favorable environment for axonal growth by the expression of a myriad of growth factors and cytokines such as neurotrophins, colony stimulating factor (CSF), interleukins, stem cell factor (SCF), NGF, BDNF, HGF and VEGF (131). They also induce angiogenesis as well as transform hostile glial environment in favor of axonal regeneration (131). In rodent studies, the effect of MSCs was more pronounced when they were grafted 7 days after injury, while IV transplantation of MSCs 4 months after SCI had no effect on motor functions as indicated by the BBB scores. It is generally proposed that this window spans between 3 days and 3 weeks after SCI (131).

3.4 Schwann cells

Schwann cells (SCs) have shown potential to myelinate axons when injected into the SCI lesion (129). Transplantation of SCs has been shown to suppresses cavity formation, promote tissue sparing, and form a bridge across the lesion site (132). SCs were able to migrate extensively in CNS and to re-myelinate axons; however, supraspinal axons failed to traverse the caudal SC-host interface, and it was difficult to maximize SC integration into the adjacent cord parenchyma (133). Further SC-precursor cells have been shown to survive, integrate and support axon growth. SCs differentiated from MSCs can meet clinical demand, while combination with other factors or cells could potentially be explored for SCI (134).

3.5. Astrocytes, a potential candidate for cell therapy

Astrocytes are the most abundant glial cells in the CNS playing pivotal roles in maintaining homeostasis (135). Recently, astrocytes are being more and more recognized as a necessary component to promote axonal re-growth after SCI (136). Those axons that previously thought to be sealed off by glial scar actually retain their regenerative potential and could still bypass the scars a full year later (130, 135). Glial scarring can protect the injured tissues and maintain the integrity of BSCB (135), while simply removing activated astrocytes would worsen the locomotive recovery (137). Astrocyte transplantation for SCI has been attempted, which revealed the potential to promote axonal regeneration and functional recovery (138). However, due to the heterogeneity of astrocytes, further studies to determine the best choice of an appropriate subpopulation is necessary (135).

3.6. Neural conversion of somatic cells

Induced pluripotency and lineage conversion have become a very interesting strategy for the treatment of SCI (139, 140). The former refers to creating ESC-like stem cells, namely induced pluripotent stem cells (iPSCs), by forced overexpression of certain transcription factors, which subsequently differentiate into target cells, while the latter is to transform one

differentiated cell type directly into another without transitioning through a pluripotent cell state (141). The creation of iPSCs by Yamanaka et al. established a complete new approach for the treatment of many diseases including SCI (142). Forced overexpression of a variety of TFs such as OCT4, Sox2, klf4, Myc, Pax6, Ngn2, Ascl1, and Dlx2, Nanog, Brn2, Myt1l, Zfp521, etc. has been utilized to convert various cell types. Among them, Ascl1 is particularly necessary for neuronal differentiation (143). A cocktail of motor neuron transcription factors were formulated to generate motor neurons (144). Numerous differentiated cell types including hepatocytes, adult astrocytes, and fibroblasts were used to generate neurons via a transient pluripotent step (145). To date, the clinical use of iPSCs is limited due to the low efficiency of current reprogramming protocols and the need of genetic modifications, which may lead to unpredicted consequences (146).

3.7. Macrophages in SCI

Recent research indicated that macrophages could be classified into two phenotypes with distinct functionalities, namely M1 and M2 (147, 148). M1 macrophages augment inflammation and tissue destruction in SCI, whereas M2 macrophages promote tissue regeneration. Depletion of M1 macrophages was shown to improve recovery (149), while augmenting M2 phenotypes promoted motor function recovery (150). Inducers for M2 macrophages such as MCP-1, ED-Siglec-9, MSCs-conditioned medium led to significant locomotive recovery in animal model studies (151). When co-transplanted with reparative M2 macrophages, NS/PC-derived neurons integrated into the local circuitry and promoted locomotive recovery (152). A biopharmaceutical company, Proneuron sponsored Phase I clinical trials for transplantation of activated macrophages in Israel and Belgium, and a randomized controlled, multicenter, Phase II clinical trial is also going on at USA and Israel hospitals (153).

3.8. Challenges in cell-based therapy for SCI

The critical challenge is obtaining sufficient quantity of purified cells. Further, SCI creates a hostile microenvironment that could affect the survival and integration of transplanted cells (123). Research is on going to understand the dynamics of implanted cells in SCI specific microenvironment and to determine the optimal window for cell therapy, which is currently proposed as 7–10 days post injury (154). Transplanted cells have varied ability to home to the spinal cord lesion or the designated location for optimal function. From this point of view, the route for cell delivery could have significant influence upon any cell-based therapy for SCI. MSCs could home to spinal lesions after intravenous injection, but this route requires larger amount of cells to ensure adequate population in the target tissue. Substantial amount of intranasally administered MSCs could home to the spinal cord lesion within 4 weeks, but the number and therapeutic effect was significantly lower than the intrathecally delivered group (155). Direct transplantation of cells to the injured spinal cord is commonly performed, but this route could lead to secondary nerve damage from needle penetration, spinal cord dislocation, intraparenchymal pressure, volume effect of cell mass and possible cord ischemia (156). Mehta et al. reported functional improvement in 31.67% patients through subarachnoid route, which avoided direct needle injury to the cord parenchyma. However this route is challenging in chronic SCI patients (157) and suggested that an optimal protocol is required to avoid potential iatrogenic problems (157). Further, potential

of a tumor-like structure formation of the transplanted cells is another challenge to overcome in order to make this approach effective and safe (158).

4. Tissue Engineering for SCI

Recent evidence indicates that the spinal cord does have minimal potential to regenerate after injury; however, due to the hostile microenvironment created by SCI, endogenous regeneration is lacking (159). Tissue engineering is aimed to rebuild damaged tissue with biocompatible scaffolds, possibly embedded with living cells (160). Numerous biomaterials have been used to develop tissue engineering scaffold for SCI including natural materials such as hyaluronic acid (HA), collagen-based matrices, chitosan, agarose, alginate, etc., as well as synthetic materials such as nitrocellulose membranes, synthetic polymers, biodegradable synthetics (131, 161). Biological grafts such as fetal spinal cord and peripheral nerve implants have also been tested. Biomaterials for SCI need to meet a list of requirements. Firstly, they must be soft enough not to compress surrounding spinal cord tissue, but structurally strong enough to sustain local fixation (162). Secondly, they must have good biocompatibility, desired porosity and permeability, and surface nanotopographies for optimal cell function (163). Thirdly, they should command a proper degradation rate in harmony with the ingrowth of supportive tissue and the extension of re-growing axons (160). Natural compound scaffolds have better performance as compared to synthetic materials in term of cell support (153, 161). In a few studies, instead of being used as cell substrate, the biomaterial scaffolds were also used for protracted release of proteins or therapeutic agents, as mentioned in previous sections (Sections 2.1.7–9) (164). The diverse types of biomaterials currently used for scaffold for SCI could be generally divided into two broad categories: hydrogels and nanofibers, the former made by process of cross-linking and polymerization, while the latter from a variety of techniques mostly based on electrospinning.

4.1. Hydrogels for tissue engineering

Hydrogels are hydrophilic polymers, which physically mimic the ECM. According to their source of origin, hydrogels could be classified into natural, synthetic, and composite materials. A variety of natural materials from normal tissue or extracellular matrix have been used to form hydrogels for tissue engineering purposes such as chitosan, collagen, hyaluronic acid, elastin, alginate, fibrinogen, laminin, gelatin, and so on (98). Synthetic hydrogels can be made from different synthetic polymers such as poly (lactic-co-glycolic acid) (PLGA), poly- ϵ -caprolactone (PCL), poly(ethylene glycol) (PEG), poly(hydroxyethyl methacrylate) (PHEMA), polyvinylalcohol (PVA), polyacrylamide, poly(hydroxypropyl methacrylate) (PHPMA), and so on (98). The purpose of placing a hydrogel is to “bridge” or fill-up the lesion to help promote functional recovery (160, 164). These hydrogels could be loaded with various pro-regenerative factors such as chondroitinase ABC, BDNF, NGF, etc (165). Compared with natural materials, synthetic hydrogels are much superior in terms of easier mass-production and property modification (166). A common drawback of synthetics is potential toxicities of contaminant or by-product, if not eliminated completely (98). Synthetic materials are often coated with natural materials to improve surface features (167).

In terms of axon regeneration, biopolymers could be ranked in the order PEG>alginate-hydrogel> Matrigel™ (168).

4.2. Nanofibers and self-assembling nanofibers for tissue engineering

Nanofiber scaffolds are essentially another kind of “hydrogel”, which are composed of nanofibers. Filling the lesion with nanofiber scaffolds made by electrospinning-based techniques is drawing attention. By enabling layer-by-layer approach, 3-D tissue printing has become realizable, while with surface functionalization, they can also be a good system for drug delivery (169). Spatial orientation of nanofibers in scaffolds can have dramatic influences upon cell polarization and function as confirmed in many cell types including neural stem cells (170). The diameter of aligned nanofibers also affects cell differentiation and neurite outgrowth, as a silk fibroin scaffold with 400 nm in fiber diameter performed much better than 800 nm ones (171).

A new methodology for nanotechnology is self-assembling (peptide) nanofibers (SAPNs). All four classes of biomolecules have been explored to generate SAPNs (172), which form nanofibers, nanotubes or nanospheres (173). These materials can be injected into the lesion in liquid form and aggregate *in situ* into a stable nano-network with physiological salt solution or changed pH (174). They fill up cavities without secondary damage, as caused by other scaffolds (175). SAPNs are composed solely of natural peptides, thus should theoretically incur no adverse effect in the recipient (176). There are several classes of SAPN materials, such as peptide amphiphiles (PA), Fmoc-peptides, self-complementary ionic peptides, hairpin peptides, and so on (177).

The peptide terminus can be functionalized with various ligands such as integrin receptor-binding sites (178), bone marrow homing proteins (173), IGF (179) or stromal cell-derived factor-1 (SDF-1) (180), sometimes there could be more than one motif separated by a diluent section (173). SAPN scaffold could possess 1000 times more functional epitopes than natural ECM (178). A commercialized SAPN, BD PuraMatrix, derived from RADA-16, when seeded with human fetal Schwann cells, reduced astrogliosis and increased S-100 positive cells in SCI rats (181). A brief summary of the current clinical trials on cell-based, and tissue engineering approaches is provided in Table 2 below.

5. Gene Therapy by way of Tissue Engineering

Since both transgenic cells and biomaterials can be modified to deliver transgene or gene products locally to the spinal cord, a combination of gene therapy and TE in the field of regenerative SCI is inevitably coming (182). The complexity of SCI provides numerous gene targets as potential treatments, such as nerve growth factors (NGF, BDNF, NT-3), regenerative cell adhesion molecules (L1, membrane-crossing mimetic peptide, plasticity-associated polysialylated neural cell adhesion molecule (PSA-NCAM)), Rho kinase inhibitors (Y-27632), transcription factors (BDNF, NT3), signaling molecules (cAMP), Nogo and LINGO-1 (182). From the point of view of tissue engineering, gene therapy for SCI could be realized in two ways: either transgenic cells delivered by supporting biomaterials as discussed above, or genetically modified tissue engineered biomaterials or scaffolds (183). PLGA scaffold loaded with NT-3 or BDNF encoding Lentivirus,

significantly increased density of regenerating axons and myelination (184). A Pluronic F-127 (PF-127) hydrogel encoding Lingo-1 shRNA knocked down Lingo-1 and significantly promoted functional recovery in complete transection SCI rats (185). Other studies also indicate biomaterial-mediated gene delivery could be a promising tool for SCI (186). Tissue engineered biomaterials as a vehicle for delivery of genetic products could become a very valuable tool to manipulate almost every aspect of SCI progression and regeneration.

6. Considerations for Pre-Clinical Study Development

There is obviously a compelling and urgent need for therapies to improve the neurologic outcome for SCI patients. The clinical evaluation of therapies that appear promising in a laboratory setting is a significant challenge, requiring considerable resources and time. Failure in such clinical trials is not only extremely costly but discouraging to the scientific community, patients, and potential investors. The scientific community has witnessed the failure of over 100 potential neuroprotective agents in clinical trials for stroke therapy (187), and this has prompted the establishment of guidelines for the preclinical evaluation of novel treatments (188), with the hope that adherence to a structure for drug development will enhance the rigor of therapies and improve their chances of success in humans.

Such guidelines do not formally exist in the SCI community around the preclinical study of novel therapies. One of the fundamental challenges is that we do not currently know which results in preclinical experiments predict success in human clinical trials. While many animal models exist and much experimentation is conducted in them, their ‘predictive validity’ remains unestablished. Most scientists would agree that treatments should show a robust effect in animal models before moving into human trials, but there is currently no consensus about ‘how much preclinical experimentation is enough’ to reach this threshold of robustness.

We have conducted a series of initiatives to poll the scientific community about this issue, and a number of preclinical considerations for successful translation have emerged from this (189–192). These include the following considerations: **A. the use of multiple animal models.** Human SCI is extremely heterogeneous, and no animal model or experimental paradigm replicates all aspects of this. Given obvious differences in the size and physiology between humans and rodents, there has been growing interest in the use of large animal and primate models of SCI. In general, there is a perception that a potential treatment is more robust if its efficacy can be demonstrated in more than one animal species. **B. the use of different injury models.** Again, related to the heterogeneity of human SCI in which the spinal cord can be variably damaged by many different mechanical forces (e.g. distraction, shear, contusion), it is thought that a potential treatment is more robust if its efficacy can be shown in experiments that employ different injury models (e.g. contusion, clip compression). **C. the window of therapeutic efficacy.** In the human setting, treatments are delivered after some inevitable delay from the time of injury. For neuroprotective agents, the efficacy is often maximal when administered before or after the time of injury. While many drugs have been shown to be efficacious in this experimental paradigm, it obviously is quite different from human reality. Treatments should therefore be shown to be efficacious in

experimental studies when administered after some sort of delay from the time of injury. One important and unresolved question is how a 1-hour post-injury delay in a rodent SCI model translates into the duration of treatment delay for a human SCI patient – is it equivalent to 1 hour? 4 hours? 8 hours? Nevertheless, it is clear that treatments should be expected to work in animal models with some length of an intervention delay, and if not, this should be addressed prior to human translation. **D. the demonstration of clinically meaningful efficacy:** It is in many ways challenging to know what sort of treatment response in animals is ‘clinically meaningful’. Preclinical studies often identify subtle yet ‘statistically significant’ changes in behavior or non-behavioral outcomes. Generally speaking, the field views behavioral recovery to be a critical component of the demonstration of efficacy, particularly when accompanied by supportive histologic outcomes. When viewing rodent studies in particular, there is a desire to observe not just ‘statistically significant’ changes but changes in which obvious changes in locomotion are evident. One of the difficulties in rodent behavior is that even after the most severe contusion type injuries, the animals recover a considerable amount of lower extremity movement, which is quite unlike human patients. **E. the demonstration of a dose-response effect:** There are two issues with dose-response: establishing that efficacy is ‘dose-dependent’ (which suggests that the efficacy is indeed attributable to the therapy) and establishing the efficacy can be achieved with realistic human doses. This is a significant consideration for drug therapies, and to some extent with cell therapies as well, where an increasing “dose” of the cells typically involves a greater volume of injection into the spinal cord. **F. the pharmacokinetics of therapy:** Many therapeutic agents (e.g. neuronal growth factors or protective agents) have poor biological stability or pharmacokinetics/ pharmacodynamics characteristics, and hence are not effective in providing therapeutic dose or maintaining their effect at the trauma site to promote regeneration and recovery. A comprehensive mechanistic understanding of the therapy is necessary to better modulate and anticipate the resulting biological response. It is important to monitor changes in the metabolism of the therapeutic drug to better infer its safety and efficacy. **G. overcoming drug resistance:** P-glycoprotein (Pgp) expression well known for its over-expression and pharmacoresistance in treatments aimed towards neurological diseases that are characterized by oxidative stress, inflammation and excitotoxicity (193, 194). Several drugs that have been assessed for SCI treatment are substrates of Pgp such as MP, riluzole and minocycline. Therefore it is conceivable to evaluate the possibility that the spinal cord can develop resistance towards Pgp thereby reducing the treatment efficacy. Dulin et al. tested this hypothesis in a contusion SCI model and observed a progressive spread of Pgp expression from 72 h up to 10 months post-SCI, which mediated a significant decline in riluzole uptake (194).

These are some of the important considerations for the preclinical development of novel therapies. Table 3 summarizes these various criteria needed for pre-clinical study design. The SCI community is currently engaged in discussions about what constitutes ‘enough’ preclinical research to justify moving forward with clinical trials, and it is expected that guidance in this important area of translation will evolve over time. Fundamentally, the community wishes to avoid the scenario of looking back at the conclusion of a failed clinical

trial and wishing that basic considerations (like dose or time window of intervention) had been tested prior to initiating clinical trials.

7. Future Outlook and Challenges

Substantial progress has been made in understanding the myriad pathological consequences after SCI as well as the advantages and limitations of various therapeutic interventions. The first challenge is to effectively inhibit the spread of secondary injury cascades. The second challenge is regeneration of the injured spinal cord and re-establishing neuronal connectivity. Since the pathology of SCI is dynamic and evolving in nature with continuous interplay between various molecular and biochemical events, treatments that are aimed at controlling just one aspect of these events are unable to regulate and control the concomitant pathways that indirectly or directly may impact the chosen pathway. A combinative approach employing the dual neuroprotective and neuroregenerative mechanisms, thus targeting multiple pathways, can provide a promising and optimal approach for the treatment of SCI. In this regard, drug delivery systems can play an important role as it can enhance drug bioavailability and specificity, sustain drug effect, can be designed to delivery combination of drugs, and mitigate serious side effects. Many of the potential therapies which have shown efficacy in preclinical studies are precluded from human studies because of unacceptable doses due to toxicity concern or unfavorable pharmacokinetics and pharmacodynamic parameters, or very short half-life that requires unacceptable dosing regimens for human studies. These issues could potentially be addressed by designating appropriate drug delivery systems. Further, certain drug delivery systems can play a dual role of controlling delivery of neuroprotective and neurogenerative therapeutics as well as acting as a scaffold for tissue engineering and cell-based therapies to promote regeneration. While some level of spontaneous recovery does occur after SCI, the intrinsic regeneration ability of the CNS is fairly limited after trauma due to the hostile microenvironment around the lesion site. Therefore, a more articulated approach that could potentially target different degenerative pathways as well as create favorable conditions for stimulating endogenous repair mechanism, in addition to exogenous treatment such as cell-based and tissue engineering approaches, in combination with growth factors and neuroprotective agents, could potentially provide an opportunity to facilitate regeneration and achieve functional restoration after SCI.

Acknowledgments

The study described in this review from author's laboratory was funded by grant R01NS092033 (to VL) from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health.

Abbreviations

SCI	Spinal Cord Injury
CNS	Central Nervous System
BSCB	Blood-spinal cord barrier
EPO	Erythropoietin

NSAID	Non-steroidal anti-inflammatory drug
MP	Methylprednisolone
FDA	Food & Drug Administration
IL-10	Interleukin-10
ChABC	Chondroitinase ABC
ROS	Reactive oxygen species
CAT	Catalase
SOD	Superoxide dismutase
CAT	Catalase
PEG	Polyethylene glycol
PLGA	Poly(lactic-co-glycolic acid)
FA	Ferulic acid
GC	Glycol chitosan
GDNF	Glial cell-derived neurotrophic factor
OEC	Olfactory-ensheathing cells
NPC	Neural progenitor cells
NSC	Neural stem cells
iPSC	Induced pluripotent stem cells
MSC	Mesenchymal stem cells
FT	Filum terminale
HGF	Hepatic growth factor
NS N	Neural sphere
ESC	Embryonic stem cells
OPC	Oligodendrocyte progenitor cells
OMC	Olfactory mucosa cells
CSF	Colony stimulating factor
SCF	Stem cell factor
SC	Schwann cells
PDA	Pre-differentiated astrocyte
HA	Hyaluronic acid
PCL	Poly- ϵ -caprolactone
PHEMA	Poly hydroxethyl methacrylate

PVA	Poly vinyl alcohol
PHPMA	Poly hydroxypropyl methacrylate
SAPN	Self-assembling (peptide) nanofibers
SDF-1	Stromal cell-derived factor-1
NGF	Nerve growth factors
PSA-NCAM	Plasticity-associated polysialylated neural cell adhesion molecule
TF	Transcription factors

References

1. Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, et al. Progress in gene therapy for neurological disorders. *Nat Rev Neurol*. 2013; 9(5):277–91. [PubMed: 23609618]
2. Spinal Cord Injury Facts & Figures at a Glance. National Spinal Cord Injury Statistical Center (NSCISC); 2013. [05/20/2015]. Available from: https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/Facts%202013.pdf
3. Schoenfeld AJ, Laughlin MD, McCrisky BJ, Bader JO, Waterman BR, Belmont PJ Jr. Spinal injuries in United States military personnel deployed to Iraq and Afghanistan: an epidemiological investigation involving 7877 combat casualties from 2005 to 2009. *Spine (Phila Pa 1976)*. 2013; 38(20):1770–8. [PubMed: 23759821]
4. Russell CM, Choo AM, Tetzlaff W, Chung TE, Oxland TR. Maximum principal strain correlates with spinal cord tissue damage in contusion and dislocation injuries in the rat cervical spine. *J Neurotrauma*. 2012; 29(8):1574–85. [PubMed: 22320127]
5. Choo AM, Liu J, Dvorak M, Tetzlaff W, Oxland TR. Secondary pathology following contusion, dislocation, and distraction spinal cord injuries. *Exp Neurol*. 2008; 212(2):490–506. [PubMed: 18561916]
6. McDonald JW, Sadowsky C. Spinal-cord injury. *Lancet*. 2002; 359(9304):417–25. [PubMed: 11844532]
7. Werndle MC, Saadoun S, Phang I, Czosnyka M, Varsos GV, Czosnyka ZH, et al. Monitoring of spinal cord perfusion pressure in acute spinal cord injury: initial findings of the injured spinal cord pressure evaluation study*. *Crit Care Med*. 2014; 42(3):646–55. [PubMed: 24231762]
8. Springer JE, Azbill RD, Knapp PE. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. *Nat Med*. 1999; 5(8):943–6. [PubMed: 10426320]
9. Silver J, Miller JH. Regeneration beyond the glial scar. *Nat Rev Neurosci*. 2004; 5(2):146–56. [PubMed: 14735117]
10. Hausmann ON. Post-traumatic inflammation following spinal cord injury. *Spinal Cord*. 2003; 41(7):369–78. [PubMed: 12815368]
11. Fawcett JW, Asher RA. The glial scar and central nervous system repair. *Brain Res Bull*. 1999; 49(6):377–91. [PubMed: 10483914]
12. Kerschensteiner M, Schwab ME, Lichtman JW, Miggelid T. In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. *Nat Med*. 2005; 11(5):572–7. [PubMed: 15821747]
13. Fehlings MG, Vaccaro A, Wilson JR, Singh A, Cadotte DW, Harrop JS, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). *PLoS one*. 2012; 7(2):e32037. [PubMed: 22384132]
14. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. *Spine J*. 2004; 4(4):451–64. [PubMed: 15246307]
15. Hamid S, Hayek R. Role of electrical stimulation for rehabilitation and regeneration after spinal cord injury: an overview. *Eur Spine J*. 2008; 17(9):1256–69. [PubMed: 18677518]

16. Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. *Nat Rev Neurosci.* 2006; 7(8):628–43. [PubMed: 16858391]
17. Rossi F, Perale G, Papa S, Forloni G, Veglianesi P. Current options for drug delivery to the spinal cord. *Expert Opin Drug Deliv.* 2013; 10(3):385–96. [PubMed: 23289716]
18. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. *Neurobiol Dis.* 2004; 16(1):1–13. [PubMed: 15207256]
19. Wiseman DB, Dailey AT, Lundin D, Zhou J, Lipson A, Falicov A, et al. Magnesium efficacy in a rat spinal cord injury model Laboratory investigation. *J Neurosurg-Spine.* 2009; 10(4):308–14. [PubMed: 19441987]
20. Donaghue IE, Tam R, Sefton MV, Shoichet MS. Cell and biomolecule delivery for tissue repair and regeneration in the central nervous system. *J Control Release.* 2014; 190:219–27. [PubMed: 24878181]
21. Jones LL, Tuszynski MH. Chronic intrathecal infusions after spinal cord injury cause scarring and compression. *Microsc Res Tech.* 2001; 54(5):317–24. [PubMed: 11514988]
22. Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, et al. The cellular inflammatory response in human spinal cords after injury. *Brain.* 2006; 129(Pt 12):3249–69. [PubMed: 17071951]
23. Kwon BK, Okon E, Hillyer J, Mann C, Baptiste D, Weaver LC, et al. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. *J Neurotrauma.* 2011; 28(8):1545–88. [PubMed: 20146558]
24. Saltzman JW, Battaglini R, Stott H, Morse LR. Neurotoxic or Neuroprotective? Current Controversies in SCI-Induced Autoimmunity. *Curr Phys Med Rehabil Rep.* 2013; 1(3):174–7.
25. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. *N Engl J Med.* 1990; 322(20):1405–11. [PubMed: 2278545]
26. Bydon M, Lin J, Macki M, Gokaslan ZL, Bydon A. The current role of steroids in acute spinal cord injury. *World neurosurg.* 2014; 82(5):848–54. [PubMed: 23454689]
27. Lee KD, Chow WN, Sato-Bigbee C, Graf MR, Graham RS, Colello RJ, et al. FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. *J Neurotrauma.* 2009; 26(12):2335–44. [PubMed: 19624262]
28. Abrams MB, Nilsson I, Lewandowski SA, Kjell J, Codeluppi S, Olson L, et al. Imatinib enhances functional outcome after spinal cord injury. *PLoS One.* 2012; 7(6):e38760. [PubMed: 22723886]
29. Pannu R, Christie DK, Barbosa E, Singh I, Singh AK. Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. *J Neurochem.* 2007; 101(1):182–200. [PubMed: 17217414]
30. Schaal SM, Garg MS, Ghosh M, Lovera L, Lopez M, Patel M, et al. The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury. *PLoS One.* 2012; 7(9):e43634. [PubMed: 23028463]
31. Iannotti CA, Clark M, Horn KP, van Rooijen N, Silver J, Steinmetz MP. A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI. *Exp Neurol.* 2011; 230(1):3–15. [PubMed: 20338167]
32. Thompson CD, Zurko JC, Hanna BF, Hellenbrand DJ, Hanna A. The therapeutic role of interleukin-10 after spinal cord injury. *J Neurotrauma.* 2013; 30(15):1311–24. [PubMed: 23731227]
33. Abraham KE, McMillen D, Brewer KL. The effects of endogenous interleukin-10 on gray matter damage and the development of pain behaviors following excitotoxic spinal cord injury in the mouse. *Neuroscience.* 2004; 124(4):945–52. [PubMed: 15026134]
34. Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP. Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. *Exp Neurol.* 2001; 168(1):144–54. [PubMed: 11170729]
35. Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. *Eur Spine J.* 2009; 18(3):314–23. [PubMed: 19030901]

36. Gensel JC, Donnelly DJ, Popovich PG. Spinal cord injury therapies in humans: an overview of current clinical trials and their potential effects on intrinsic CNS macrophages. *Expert Opin Ther Tar.* 2011; 15(4):505–18.
37. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. *Neurosurg Rev.* 2004; 27(2):113–20. [PubMed: 12920606]
38. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature.* 2002; 416(6881):636–40. [PubMed: 11948352]
39. Alilain WJ, Horn KP, Hu H, Dick TE, Silver J. Functional regeneration of respiratory pathways after spinal cord injury. *Nature.* 2011; 475(7355):196–200. [PubMed: 21753849]
40. Bartus K, James ND, Didangelos A, Bosch KD, Verhaagen J, Yanez-Munoz RJ, et al. Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury. *J Neurosci.* 2014; 34(14):4822–36. [PubMed: 24695702]
41. Yiu G, He Z. Glial inhibition of CNS axon regeneration. *Nat Rev Neurosci.* 2006; 7(8):617–27. [PubMed: 16858390]
42. Liebscher T, Schnell L, Schnell D, Scholl J, Schneider R, Gullo M, et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. *Ann Neurol.* 2005; 58(5):706–19. [PubMed: 16173073]
43. Freund P, Schmidlin E, Wannier T, Bloch J, Mir A, Schwab ME, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. *Nat Med.* 2006; 12(7):790–2. [PubMed: 16819551]
44. Blits B, Oudega M, Boer GJ, Bartlett Bunge M, Verhaagen J. Adeno-associated viral vector-mediated neurotrophin gene transfer in the injured adult rat spinal cord improves hind-limb function. *Neuroscience.* 2003; 118(1):271–81. [PubMed: 12676157]
45. Hougland MT, Harrison BJ, Magnuson DS, Rouchka EC, Petruska JC. The transcriptional response of neurotrophins and their tyrosine kinase receptors in lumbar sensorimotor circuits to spinal cord contusion is affected by injury severity and survival time. *Front Physiol.* 2012;3. [PubMed: 22279436]
46. Das A, Sribnick EA, Wingrave JM, Del Re AM, Woodward JJ, Appel SH, et al. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. *J Neurosci Res.* 2005; 81(4):551–62. [PubMed: 15968645]
47. Ray SK, Wilford GG, Matzelle DC, Hogan EL, Banik NL. Calpeptin and methylprednisolone inhibit apoptosis in rat spinal cord injury. *Ann N Y Acad Sci.* 1999; 890(1):261–9. [PubMed: 10668431]
48. Yu CG, Joshi A, Geddes JW. Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury. *J Neurotrauma.* 2008; 25(7):833–40. [PubMed: 18627259]
49. Davis RJ. Signal transduction by the JNK group of MAP kinases. *Cell.* 2000; 103(2):239–52. [PubMed: 11057897]
50. Gao YJ, Ji RR. Targeting astrocyte signaling for chronic pain. *Neurotherapeutics.* 2010; 7(4):482–93. [PubMed: 20880510]
51. Repici M, Chen X, Morel MP, Doulazmi M, Sclip A, Cannaya V, et al. Specific inhibition of the JNK pathway promotes locomotor recovery and neuroprotection after mouse spinal cord injury. *Neurobiol Dis.* 2012; 46(3):710–21. [PubMed: 22426389]
52. Yacoub A, Hajec MC, Stanger R, Wan W, Young H, Mathern BE. Neuroprotective effects of perfluorocarbon (oxycyte) after contusive spinal cord injury. *J Neurotrauma.* 2014; 31(3):256–67. [PubMed: 24025081]
53. Paterniti I, Mazzon E, Emanuela E, Paola RD, Galuppo M, Bramanti P, et al. Modulation of inflammatory response after spinal cord trauma with deferroxamine, an iron chelator. *Free Radic Res.* 2010; 44(6):694–709. [PubMed: 20370565]

54. Rathore KI, Kerr BJ, Redensek A, Lopez-Vales R, Jeong SY, Ponka P, et al. Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage. *J Neurosci*. 2008; 28(48): 12736–47. [PubMed: 19036966]
55. Schultke E, Griebel RW, Juurlink BH. Quercetin attenuates inflammatory processes after spinal cord injury in an animal model. *Spinal cord*. 2010; 48(12):857–61. [PubMed: 20440299]
56. Sauerbeck A, Schonberg DL, Laws JL, McTigue DM. Systemic iron chelation results in limited functional and histological recovery after traumatic spinal cord injury in rats. *Exp Neurol*. 2013; 248:53–61. [PubMed: 23712107]
57. Hall ED. Antioxidant therapies for acute spinal cord injury. *Neurotherapeutics*. 2011; 8(2):152–67. [PubMed: 21424941]
58. Emery E, Aldana P, Bunge MB, Puckett W, Srinivasan A, Keane RW, et al. Apoptosis after traumatic human spinal cord injury. *J Neurosurg*. 1998; 89(6):911–20. [PubMed: 9833815]
59. Hamann K, Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. *J Neurochem*. 2009; 111(6):1348–56. [PubMed: 19780896]
60. Park J, Zheng L, Marquis A, Walls M, Duerstock B, Pond A, et al. Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage. *J Neurochem*. 2014; 129(2):339–49. [PubMed: 24286176]
61. Reece PA. Hydralazine and related compounds: chemistry, metabolism, and mode of action. *Med Res Rev*. 1981; 1(1):73–96. [PubMed: 7050561]
62. Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. *Biochim Biophys Acta*. 2012; 1822(5):675–84. [PubMed: 22080976]
63. Wu Q, Jing Y, Yuan X, Zhang X, Li B, Liu M, et al. Melatonin treatment protects against acute spinal cord injury-induced disruption of blood spinal cord barrier in mice. *J Mol Neurosci*. 2014; 54(4):714–22. [PubMed: 25303856]
64. Schiaveto-de-Souza A, da-Silva CA, Defino HL, Del Bel EA. Effect of melatonin on the functional recovery from experimental traumatic compression of the spinal cord. *Braz J Med Biol Res*. 2013; 46(4):348–58. [PubMed: 23579633]
65. Gul S, Celik SE, Kalayci M, Tasyurekli M, Cokar N, Bilge T. Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats. *Surg Neurol*. 2005; 64(4):355–61. [PubMed: 16231427]
66. Fujimoto T, Nakamura T, Ikeda T, Takagi K. Potent protective effects of melatonin on experimental spinal cord injury. *Spine (Phila Pa 1976)*. 2000; 25(7):769–75. [PubMed: 10751286]
67. Hong Y, Palaksha KJ, Park K, Park S, Kim HD, Reiter RJ, et al. Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury. *J Pineal Res*. 2010; 49(3):201–9. [PubMed: 20626592]
68. Cristante AF, Barros Filho TE, Oliveira RP, Marcon RM, Rocha ID, Hanania FR, et al. Antioxidative therapy in contusion spinal cord injury. *Spinal cord*. 2009; 47(6):458–63. [PubMed: 19065150]
69. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. *J Neurotrauma*. 2000; 17(10): 871–90. [PubMed: 11063054]
70. Gorgulu A, Kiris T, Unal F, Turkoglu U, Kucuk M, Cobanoglu S. Superoxide dismutase activity and the effects of NBQX and CPP on lipid peroxidation in experimental spinal cord injury. *Res Exp Med (Berl)*. 2000; 199(5):285–93. [PubMed: 10815757]
71. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. *Curr Neuropharmacol*. 2009; 7(1):65–74. [PubMed: 19721819]
72. Azbill RD, Mu X, Bruce-Keller AJ, Mattson MP, Springer JE. Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury. *Brain Res*. 1997; 765(2):283–90. [PubMed: 9313901]
73. Wang C-Y, Chen J-K, Wu Y-T, Tsai M-J, Shyue S-K, Yang C-S, et al. Reduction in antioxidant enzyme expression and sustained inflammation enhance tissue damage in the subacute phase of spinal cord contusive injury. *J Biomed Sci*. 2011; 18(13):932–43.
74. Kucur M, Tanriverdi T, Dashti R, Ak H, Yentur E, Belce A, et al. Superoxide dismutase, catalase, and guanase in traumatic brain injury. *Neurosurg Quart*. 2005; 15(3):186–9.

75. Francis JW, Ren J, Warren L, Brown RH Jr, Finklestein SP. Postischemic infusion of Cu/Zn superoxide dismutase or SOD:Tet451 reduces cerebral infarction following focal ischemia/reperfusion in rats. *Exp Neurol*. 1997; 146(2):435–43. [PubMed: 9270054]
76. Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. *J Cereb Blood Flow Metab*. 2004; 24(4):351–71. [PubMed: 15087705]
77. Tsubokawa T, Jadhav V, Solaroglu I, Shiokawa Y, Konishi Y, Zhang JH. Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. *Stroke*. 2007; 38(3):1057–62. [PubMed: 17272760]
78. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. *Adv Drug Deliv Rev*. 2002; 54(4):587–606. [PubMed: 12052716]
79. Imaizumi S, Woolworth V, Fishman RA, Chan PH. Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. *Stroke*. 1990; 21(9):1312–7. [PubMed: 2396268]
80. Sinha J, Das N, Basu MK. Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain. *Biomed Pharmacother*. 2001; 55(5):264–71. [PubMed: 11428552]
81. Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. *Appl Biochem Biotechnol*. 2008; 151(2–3):565–77. [PubMed: 18509606]
82. Ghorpade ASA, Morris A, Labhasetwar V. Nanoparticle-mediated catalase delivery protects human neurons from oxidative stress. *Cell Death Dis*. 2013; 4:e903. [PubMed: 24201802]
83. Tyler JY, Xu XM, Cheng JX. Nanomedicine for treating spinal cord injury. *Nanoscale*. 2013; 5(19):8821–36. [PubMed: 23945984]
84. Kim YT, Caldwell JM, Bellamkonda RV. Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury. *Biomaterials*. 2009; 30(13):2582–90. [PubMed: 19185913]
85. Cerqueira SR, Oliveira JM, Silva NA, Leite-Almeida H, Ribeiro-Samy S, Almeida A, et al. Microglia response and in vivo therapeutic potential of methylprednisolone-loaded dendrimer nanoparticles in spinal cord injury. *Small*. 2013; 9(5):738–49. [PubMed: 23161735]
86. Wu W, Lee SY, Wu X, Tyler JY, Wang H, Ouyang Z, et al. Neuroprotective ferulic acid (FA)-glycol chitosan (GC) nanoparticles for functional restoration of traumatically injured spinal cord. *Biomaterials*. 2014; 35(7):2355–64. [PubMed: 24332460]
87. Saxena T, Loomis KH, Pai SB, Karumbaiah L, Gaupp E, Patil K, et al. Nanocarrier-mediated inhibition of macrophage migration inhibitory factor attenuates secondary injury after spinal cord injury. *ACS Nano*. 2015; 9(2):1492–505. [PubMed: 25587936]
88. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. *Nat Rev Neurosci*. 2011; 12(7):388–99. [PubMed: 21673720]
89. Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. *Expert Opin Drug Deliv*. 2013; 10(3):353–67. [PubMed: 23289618]
90. Papa S, Rossi F, Ferrari R, Mariani A, De Paola M, Caron I, et al. Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury. *ACS Nano*. 2013; 7(11):9881–95. [PubMed: 24138479]
91. Cho Y, Shi R, Ivanisevic A, Borgens RB. Functional silica nanoparticle-mediated neuronal membrane sealing following traumatic spinal cord injury. *J Neurosci Res*. 2010; 88(7):1433–44. [PubMed: 19998478]
92. Wang YC, Wu YT, Huang HY, Lin HI, Lo LW, Tzeng SF, et al. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. *Biomaterials*. 2008; 29(34):4546–53. [PubMed: 18774604]
93. Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV. Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. *Biomaterials*. 2008; 29(12):1967–75. [PubMed: 18255138]
94. Pakulska MM, Vulic K, Shoichet MS. Affinity-based release of chondroitinase ABC from a modified methylcellulose hydrogel. *J Control Release*. 2013; 171(1):11–6. [PubMed: 23831055]

95. Lee H, McKeon RJ, Bellamkonda RV. Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. *Proc Natl Acad Sci U S A*. 2010; 107(8):3340–5. [PubMed: 19884507]
96. Awad BI, Carmody MA, Steinmetz MP. Potential role of growth factors in the management of spinal cord injury. *World Neurosurg*. 2015; 83(1):120–31. [PubMed: 23334003]
97. Macaya D, Spector M. Injectable hydrogel materials for spinal cord regeneration: a review. *Biomed Mater*. 2012; 7(1):012001. [PubMed: 22241481]
98. Perale G, Rossi F, Sundstrom E, Bacchiega S, Masi M, Forloni G, et al. Hydrogels in spinal cord injury repair strategies. *ACS Chem Neurosci*. 2011; 2(7):336–45. [PubMed: 22816020]
99. des Rieux A, De Berdt P, Ansorena E, Ucakar B, Damien J, Schakman O, et al. Vascular endothelial growth factor-loaded injectable hydrogel enhances plasticity in the injured spinal cord. *J Biomed Mater Res A*. 2014; 102(7):2345–55. [PubMed: 23946111]
100. Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. *Brain*. 2012; 135(Pt 4):1224–36. [PubMed: 22505632]
101. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. *J Neurochem*. 2006; 97(5):1314–26. [PubMed: 16638021]
102. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. *J Neurosci*. 2004; 24(9):2182–90. [PubMed: 14999069]
103. Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. *J Neurosurg Spine*. 2012; 17(1 Suppl):151–6. [PubMed: 22985381]
104. Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). *Neuroscience*. 2004; 125(1):191–201. [PubMed: 15051158]
105. Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. *J Neurosurg*. 2001; 94(2 Suppl):245–56. [PubMed: 11302627]
106. Chow DS, Teng Y, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, et al. Pharmacology of riluzole in acute spinal cord injury. *J Neurosurg Spine*. 2012; 17(1 Suppl):129–40. [PubMed: 22985379]
107. Fehlings MG, Theodore N, Harrop J, Maurais G, Kuntz C, Shaffrey CI, et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. *J Neurotrauma*. 2011; 28(5):787–96. [PubMed: 21381984]
108. Lord-Fontaine S, Yang F, Diep Q, Dergham P, Munzer S, Tremblay P, et al. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. *J Neurotrauma*. 2008; 25(11):1309–22. [PubMed: 19061375]
109. Gorio A, Madaschi L, Di Stefano B, Carelli S, Di Giulio AM, De Biasi S, et al. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. *Proc Natl Acad Sci U S A*. 2005; 102(45):16379–84. [PubMed: 16260722]
110. Vitellaro-Zuccarello L, Mazzetti S, Madaschi L, Bosisio P, Gorio A, De Biasi S. Erythropoietin-mediated preservation of the white matter in rat spinal cord injury. *Neuroscience*. 2007; 144(3):865–77. [PubMed: 17141961]
111. Dalla Costa D, Beghi E, Carignano P, Pagliacci C, Faccioli F, Pupillo E, et al. Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP). *Neurol Sci*. 2015; 1–8. [PubMed: 26017501]
112. Zorner B, Schwab ME. Anti-Nogo on the go: from animal models to a clinical trial. *Ann N Y Acad Sci*. 2010; 1198(Suppl 1 s1):E22–34. [PubMed: 20590535]

113. Cardenas D, Ditunno J, Graziani V, Jackson A, Lammertse D, Potter P, et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. *Spinal cord*. 2007; 45(2):158–68. [PubMed: 16773037]
114. Cardenas D, Ditunno J, Graziani V, McLain A, Lammertse D, Potter P, et al. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. *Spinal cord*. 2014; 52(1):70–6. [PubMed: 24216616]
115. Wang X, Xu XM. Long-term survival, axonal growth-promotion, and myelination of Schwann cells grafted into contused spinal cord in adult rats. *Exp Neurol*. 2014; 261:308–19. [PubMed: 24873728]
116. Park DY, Mayle RE, Smith RL, Corcoran-Schwartz I, Kharazi AI, Cheng I. Combined Transplantation of Human Neuronal and Mesenchymal Stem Cells following Spinal Cord Injury. *Global Spine J*. 2013; 3(1):1–6. [PubMed: 24436845]
117. Yang H, Liu CC, Wang CY, Zhang Q, An J, Zhang L, et al. Therapeutical Strategies for Spinal Cord Injury and a Promising Autologous Astrocyte-Based Therapy Using Efficient Reprogramming Techniques. *Mol Neurobiol*. 2015 Epub ahead of print.
118. Kanno H, Pressman Y, Moody A, Berg R, Muir EM, Rogers JH, et al. Combination of engineered Schwann cell grafts to secrete neurotrophin and chondroitinase promotes axonal regeneration and locomotion after spinal cord injury. *J Neurosci*. 2014; 34(5):1838–55. [PubMed: 24478364]
119. Ebina W, Rossi DJ. Transcription factor-mediated reprogramming toward hematopoietic stem cells. *EMBO J*. 2015; 34(6):694–709. [PubMed: 25712209]
120. Slovinska L, Szekiova E, Blasko J, Devaux S, Salzert M, Cizkova D. Comparison of dynamic behavior and maturation of neural multipotent cells derived from different spinal cord developmental stages: an in vitro study. *Acta Neurobiol Exp (Wars)*. 2015; 75(1):107–14. [PubMed: 25856526]
121. Jha RM, Chrenek R, Magnotti LM, Cardozo DL. The isolation, differentiation, and survival in vivo of multipotent cells from the postnatal rat filum terminale. *PLoS One*. 2013; 8(6):e65974. [PubMed: 23762453]
122. Wang C, Luan Z, Yang Y, Wang Z, Wang Q, Lu Y, et al. High purity of human oligodendrocyte progenitor cells obtained from neural stem cells: suitable for clinical application. *J Neurosci Methods*. 2015; 240:61–6. [PubMed: 25445251]
123. Potter W, Kalil RE, Kao WJ. Biomimetic material systems for neural progenitor cell-based therapy. *Front Biosci*. 2008; 13:806–21. [PubMed: 17981590]
124. Barnett SC, Riddell JS. Olfactory ensheathing cells (OECs) and the treatment of CNS injury: advantages and possible caveats. *J Anat*. 2004; 204(1):57–67. [PubMed: 14690478]
125. Farbman AI. Olfactory neurogenesis: genetic or environmental controls? *Trends Neurosci*. 1990; 13(9):362–5. [PubMed: 1699323]
126. Li Y, Field PM, Raisman G. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. *Science*. 1997; 277(5334):2000–2. [PubMed: 9302296]
127. Tabakow P, Jarmundowicz W, Czapiga B, Fortuna W, Miedzybrodzki R, Czyz M, et al. Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. *Cell Transplant*. 2013; 22(9):1591–612. [PubMed: 24007776]
128. Ishihara M, Mochizuki-Oda N, Iwatsuki K, Kishima H, Ohnishi Y, Moriwaki T, et al. Primary olfactory mucosal cells promote axonal outgrowth in a three-dimensional assay. *J Neurosci Res*. 2014; 92(7):847–55. [PubMed: 24532304]
129. Mehrabi S, Eftekhari S, Moradi F, Delaviz H, Pourheidari B, Azizi M, et al. Cell therapy in spinal cord injury: a mini-review. *Basic Clin Neurosci*. 2013; 4(2):172–6. [PubMed: 25337345]
130. Dlouhy BJ, Awe O, Rao RC, Kirby PA, Hitchon PW. Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient: Case report. *J Neurosurg Spine*. 2014; 21(4):618–22. [PubMed: 25002238]
131. Sykova E, Jendelova P, Urdzikova L, Lesny P, Hejcl A. Bone marrow stem cells and polymer hydrogels—two strategies for spinal cord injury repair. *Cell Mol Neurobiol*. 2006; 26(7–8):1113–29. [PubMed: 16633897]
132. Kamada T, Koda M, Dezawa M, Anahara R, Toyama Y, Yoshinaga K, et al. Transplantation of human bone marrow stromal cell-derived Schwann cells reduces cystic cavity and promotes

- functional recovery after contusion injury of adult rat spinal cord. *Neuropathology*. 2011; 31(1): 48–58. [PubMed: 20573032]
133. Bunge MB, Wood PM. Realizing the maximum potential of Schwann cells to promote recovery from spinal cord injury. *Handb Clin Neurol*. 2012; 109:523–40. [PubMed: 23098734]
 134. Kanno H, Pearse DD, Ozawa H, Itoi E, Bunge MB. Schwann cell transplantation for spinal cord injury repair: its significant therapeutic potential and prospectus. *Rev Neurosci*. 2015; 26(2):121–8. [PubMed: 25581750]
 135. Chu T, Zhou H, Li F, Wang T, Lu L, Feng S. Astrocyte transplantation for spinal cord injury: current status and perspective. *Brain Res Bull*. 2014; 107:18–30. [PubMed: 24878447]
 136. Nicaise C, Mitrecic D, Falnikar A, Lepore AC. Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury. *World J Stem Cells*. 2015; 7(2):380–98. [PubMed: 25815122]
 137. Maier IC, Schwab ME. Sprouting, regeneration and circuit formation in the injured spinal cord: factors and activity. *Philos Trans R Soc Lond B Biol Sci*. 2006; 361(1473):1611–34. [PubMed: 16939978]
 138. Fan C, Zheng Y, Cheng X, Qi X, Bu P, Luo X, et al. Transplantation of D15A-expressing glial-restricted-precursor-derived astrocytes improves anatomical and locomotor recovery after spinal cord injury. *Int J Biol Sci*. 2013; 9(1):78–93. [PubMed: 23289019]
 139. Ichida JK, Kiskinis E. Probing disorders of the nervous system using reprogramming approaches. *EMBO J*. 2015 pii: e201591267. Epub ahead of print.
 140. Havasi P, Soleimani M, Morovvati H, Bakhshandeh B, Nabiuni M. The proliferation study of hips cell-derived neuronal progenitors on poly-caprolactone scaffold. *Basic Clin Neurosci*. 2014; 5(2):117–23. [PubMed: 25337369]
 141. Corti S, Nizzardo M, Simone C, Falcone M, Donadoni C, Salani S, et al. Direct reprogramming of human astrocytes into neural stem cells and neurons. *Exp Cell Res*. 2012; 318(13):1528–41. [PubMed: 22426197]
 142. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126(4):663–76. [PubMed: 16904174]
 143. Wapinski OL, Vierbuchen T, Qu K, Lee QY, Chanda S, Fuentes DR, et al. Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. *Cell*. 2013; 155(3):621–35. [PubMed: 24243019]
 144. Son EY, Ichida JK, Wainger BJ, Toma JS, Rafuse VF, Woolf CJ, et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. *Cell Stem Cell*. 2011; 9(3):205–18. [PubMed: 21852222]
 145. Caiazzo M, Giannelli S, Valente P, Lignani G, Carissimo A, Sessa A, et al. Direct conversion of fibroblasts into functional astrocytes by defined transcription factors. *Stem Cell Reports*. 2015; 4(1):25–36. [PubMed: 25556566]
 146. Loh YH, Yang JC, De Los Angeles A, Guo C, Cherry A, Rossi DJ, et al. Excision of a viral reprogramming cassette by delivery of synthetic Cre mRNA. *Curr Protoc Stem Cell Biol*. 2012; Chapter 4(Unit4A 5)
 147. Novak ML, Koh TJ. Macrophage phenotypes during tissue repair. *J Leukoc Biol*. 2013; 93(6): 875–81. [PubMed: 23505314]
 148. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000prime reports*. 2014; 6:13. [PubMed: 24669294]
 149. Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. *Exp Neurol*. 2008; 209(2):378–88. [PubMed: 17662717]
 150. Schwartz M, Yoles E. Immune-based therapy for spinal cord repair: autologous macrophages and beyond. *J Neurotrauma*. 2006; 23(3–4):360–70. [PubMed: 16629622]
 151. Matsubara K, Matsushita Y, Sakai K, Kano F, Kondo M, Noda M, et al. Secreted ectodomain of sialic acid-binding Ig-like lectin-9 and monocyte chemoattractant protein-1 promote recovery after rat spinal cord injury by altering macrophage polarity. *J Neurosci*. 2015; 35(6):2452–64. [PubMed: 25673840]

152. Zhang K, Zheng JJ, Bian GL, Liu L, Xue Q, Liu FF, et al. Polarized Macrophages Have Distinct Roles in the Differentiation and Migration of Embryonic Spinal-cord-derived Neural Stem Cells After Grafting to Injured Sites of Spinal Cord. *Mol Ther*. 2015; 23(6):1077–91. [PubMed: 25794051]
153. Wu MC, Yuan H, Li KJ, Qiu DL. Cellular transplantation-based evolving treatment options in spinal cord injury. *Cell Biochem Biophys*. 2015; 71(1):1–8. [PubMed: 25120021]
154. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, Hill CE, Sparling JS, Plemel JR, et al. A systematic review of cellular transplantation therapies for spinal cord injury. *J Neurotrauma*. 2011; 28(8): 1611–82. [PubMed: 20146557]
155. Ninomiya K, Iwatsuki K, Ohnishi Y, Ohkawa T, Yoshimine T. Intranasal delivery of bone marrow stromal cells to spinal cord lesions. *J Neurosurg Spine*. 2015; 23(1):111–9. [PubMed: 25840039]
156. Lee HY, Lee HL, Yun Y, Kim JS, Ha Y, Yoon do H, et al. Human Adipose Stem Cells Improve Mechanical Allodynia and Enhance Functional Recovery in a Rat Model of Neuropathic Pain. *Tissue Eng Part A*. 2015; 21(13–14):2044–52. [PubMed: 25857679]
157. Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H. Subarachnoid placement of stem cells in neurological disorders. *Transplant Proc*. 2008; 40(4):1145–7. [PubMed: 18555135]
158. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. *Nat Med*. 2013; 19(8):998–1004. [PubMed: 23921754]
159. Siddiqui AM, Khazaei M, Fehlings MG. Translating mechanisms of neuroprotection, regeneration, and repair to treatment of spinal cord injury. *Prog Brain Res*. 2015; 218:15–54. [PubMed: 25890131]
160. Kubinova S, Sykova E. Nanotechnologies in regenerative medicine. *Minim Invasive Ther Allied Technol*. 2010; 19(3):144–56. [PubMed: 20497067]
161. Madigan NN, McMahon S, O'Brien T, Yaszemski MJ, Windebank AJ. Current tissue engineering and novel therapeutic approaches to axonal regeneration following spinal cord injury using polymer scaffolds. *Respir Physiol Neurobiol*. 2009; 169(2):183–99. [PubMed: 19737633]
162. Rooney GE, Vaishya S, Ameenuddin S, Currier BL, Schiefer TK, Knight A, et al. Rigid fixation of the spinal column improves scaffold alignment and prevents scoliosis in the transected rat spinal cord. *Spine (Phila Pa 1976)*. 2008; 33(24):E914–9. [PubMed: 19011531]
163. Wang J, Zheng J, Zheng Q, Wu Y, Wu B, Huang S, et al. FGL-functionalized self-assembling nanofiber hydrogel as a scaffold for spinal cord-derived neural stem cells. *Mater Sci Eng C Mater Biol Appl*. 2015; 46:140–7. [PubMed: 25491970]
164. Tabata Y. Biomaterial technology for tissue engineering applications. *J R Soc Interface*. 2009; 6(Suppl 3):S311–24. [PubMed: 19324684]
165. Jain A, McKeon RJ, Brady-Kalnay SM, Bellamkonda RV. Sustained delivery of activated Rho GTPases and BDNF promotes axon growth in CSPG-rich regions following spinal cord injury. *PLoS One*. 2011; 6(1):e16135. [PubMed: 21283639]
166. Shoichet MS. Polymer Scaffolds for Biomaterials Applications. *Macromolecules*. 2010; 43(2): 581–91.
167. Thouas GA, Contreras KG, Bernard CC, Sun GZ, Tsang K, Zhou K, et al. Biomaterials for spinal cord regeneration: outgrowth of presumptive neuronal precursors on electrospun poly(epsilon)-caprolactone scaffolds microlayered with alternating polyelectrolytes. *Conf Proc IEEE Eng Med Biol Soc*. 2008; 2008:1825–8. [PubMed: 19163037]
168. Estrada V, Brazda N, Schmitz C, Heller S, Blazycza H, Martini R, et al. Long-lasting significant functional improvement in chronic severe spinal cord injury following scar resection and polyethylene glycol implantation. *Neurobiol Dis*. 2014; 67:165–79. [PubMed: 24713436]
169. Yang X, Shah JD, Wang H. Nanofiber enabled layer-by-layer approach toward three-dimensional tissue formation. *Tissue Eng Part A*. 2009; 15(4):945–56. [PubMed: 18788981]
170. Lee JH, Lee YJ, Cho HJ, Shin H. Guidance of in vitro migration of human mesenchymal stem cells and in vivo guided bone regeneration using aligned electrospun fibers. *Tissue Eng Part A*. 2014; 20(15–16):2031–42. [PubMed: 24206080]

171. Wang J, Ye R, Wei Y, Wang H, Xu X, Zhang F, et al. The effects of electrospun TSF nanofiber diameter and alignment on neuronal differentiation of human embryonic stem cells. *J Biomed Mater Res A*. 2012; 100(3):632–45. [PubMed: 22213384]
172. Busseron E, Ruff Y, Moulin E, Giuseppone N. Supramolecular self-assemblies as functional nanomaterials. *Nanoscale*. 2013; 5(16):7098–140. [PubMed: 23832165]
173. Gelain F, Bottai D, Vescovi A, Zhang S. Designer self-assembling peptide nanofiber scaffolds for adult mouse neural stem cell 3-dimensional cultures. *PLoS One*. 2006; 1:e119. [PubMed: 17205123]
174. Zweckberger K, Liu Y, Wang J, Forgione N, Fehlings MG. Synergetic use of neural precursor cells and self-assembling peptides in experimental cervical spinal cord injury. *J Vis Exp*. 2015; (96):e52105. [PubMed: 25742521]
175. Liu Y, Ye H, Satkunendrarajah K, Yao GS, Bayon Y, Fehlings MG. A self-assembling peptide reduces glial scarring, attenuates post-traumatic inflammation and promotes neurological recovery following spinal cord injury. *Acta Biomater*. 2013; 9(9):8075–88. [PubMed: 23770224]
176. Schmidt CE, Leach JB. Neural tissue engineering: strategies for repair and regeneration. *Annu Rev Biomed Eng*. 2003; 5:293–347. [PubMed: 14527315]
177. Matson JB, Stupp SI. Self-assembling peptide scaffolds for regenerative medicine. *Chem Commun (Camb)*. 2012; 48(1):26–33. [PubMed: 22080255]
178. Silva GA, Czeisler C, Niece KL, Beniash E, Harrington DA, Kessler JA, et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. *Science*. 2004; 303(5662):1352–5. [PubMed: 14739465]
179. Davis ME, Hsieh PC, Takahashi T, Song Q, Zhang S, Kamm RD, et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. *Proc Natl Acad Sci U S A*. 2006; 103(21):8155–60. [PubMed: 16698918]
180. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. *Circulation*. 2007; 116(15):1683–92. [PubMed: 17875967]
181. Moradi F, Bahktiari M, Joghataei MT, Nobakht M, Soleimani M, Hasanzadeh G, et al. BD PuraMatrix peptide hydrogel as a culture system for human fetal Schwann cells in spinal cord regeneration. *J Neurosci Res*. 2012; 90(12):2335–48. [PubMed: 22996688]
182. Franz S, Weidner N, Blesch A. Gene therapy approaches to enhancing plasticity and regeneration after spinal cord injury. *Exp Neurol*. 2012; 235(1):62–9. [PubMed: 21281633]
183. Walthers CM, Seidlits SK. Gene delivery strategies to promote spinal cord repair. *Biomark Insights*. 2015; 10(Suppl 1):11–29. [PubMed: 25922572]
184. Tuinstra HM, Aviles MO, Shin S, Holland SJ, Zelivyanskaya ML, Fast AG, et al. Multifunctional, multichannel bridges that deliver neurotrophin encoding lentivirus for regeneration following spinal cord injury. *Biomaterials*. 2012; 33(5):1618–26. [PubMed: 22130565]
185. Wu HF, Cen JS, Zhong Q, Chen L, Wang J, Deng DY, et al. The promotion of functional recovery and nerve regeneration after spinal cord injury by lentiviral vectors encoding Lingo-1 shRNA delivered by Pluronic F-127. *Biomaterials*. 2013; 34(6):1686–700. [PubMed: 23211450]
186. Thomas AM, Seidlits SK, Goodman AG, Kukushliev TV, Hassani DM, Cummings BJ, et al. Sonic hedgehog and neurotrophin-3 increase oligodendrocyte numbers and myelination after spinal cord injury. *Integr Biol (Camb)*. 2014; 6(7):694–705. [PubMed: 24873988]
187. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. *Ann Neurol*. 2006; 59(3):467–77. [PubMed: 16453316]
188. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke*. 2009; 40(6):2244–50. [PubMed: 19246690]
189. Kwon BK, Streijger F, Hill CE, Anderson AJ, Bacon M, Beattie MS, et al. Large animal and primate models of spinal cord injury for the testing of novel therapies. *Exp Neurol*. 2015; 269:154–68. [PubMed: 25902036]

190. Kwon BK, Ghag A, Reichl L, Dvorak MF, Illes J, Tetzlaff W. Opinions on the preclinical evaluation of novel therapies for spinal cord injury: a comparison between researchers and spinal cord-injured individuals. *J Neurotrauma*. 2012; 29(14):2367–74. [PubMed: 22776047]
191. Kwon BK, Okon EB, Tsai E, Beattie MS, Bresnahan JC, Magnuson DK, et al. A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury. *J Neurotrauma*. 2011; 28(8):1525–43. [PubMed: 20507235]
192. Kwon BK, Hillyer J, Tetzlaff W. Translational research in spinal cord injury: a survey of opinion from the SCI community. *J Neurotrauma*. 2010; 27(1):21–33. [PubMed: 19751098]
193. Milane A, Fernandez C, Dupuis L, Buyse M, Loeffler J-P, Farinotti R, et al. P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. *Neuroscience letters*. 2010; 472(3):166–70. [PubMed: 20138122]
194. Dulin JN, Moore ML, Grill RJ. The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord. *J Neurotrauma*. 2013; 30(3):211–26. [PubMed: 22947335]

Figure 1.
Progression of spinal cord injury response with time and different therapeutic and regenerative strategies.

Figure 2. Neuroprotective efficacy of SOD-NPs in human neurons

(A) SOD-NPs (superoxide dismutase-loaded nanoparticles) using different doses of SOD at 6 hrs in neurons under hydrogen peroxide-induced oxidative stress; (B) Comparative neuroprotective effect of SOD-NPs with pegylated-SOD (PEG-SOD) in neurons under hydrogen peroxide-induced oxidative stress, Dose of SOD = 100 U (Data as mean + s.e.m.; n = 3; *P < 0.05). Figure reproduced with permission from reference (81).

Figure 3. Nano-CAT-NPs protect human neuronal cells from oxidative stress

Primary human neurons were challenged with hydrogen peroxide-induced oxidative (50 μ M, 24 h) with or without 200 μ g/ml Nano-CAT (catalase-loaded NPs) or Nano-CON (control NPs without CAT) and stained for microtubule associated protein 2 (MAP-2). Immunostaining micrographs (a–f) show MAP-2 staining (red, neuronal marker; specific cytoskeletal proteins that are enriched in dendrites and essential to stabilize its shape); Glial fibrillary acidic protein (GFAP, green, astrocyte marker); and 4',6-diamidino-2-phenylindole (DAPI, blue, nuclei). Arrow represents loss of MAP-2, neurite network or fragmented nuclei. Arrowhead represents MAP-2 enriched neurons. Images are representative of five random fields of at three donors. Scale bar = 50 μ m. Reproduced with permission from reference (82).

Table 1

Clinical trials based on drug therapies

TITLE	INTERVENTIONS	PHASE	ID
Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury	Drug: Minocycline Drug: placebo Procedure: SCPP augmentation Procedure: SCPP control	Phase 1 Phase 2	NCT00559494
Minocycline in Acute Spinal Cord Injury (MASC)	Drug: Minocycline Drug: Placebo Procedure: Surgical spinal cord decompression Procedure: Maintenance of minimum mean arterial pressure (MAP)	Phase 3	NCT01828203
Safety of Riluzole in Patients With Acute Spinal Cord Injury	Drug: Riluzole	Phase 2	NCT00876889
Riluzole in Spinal Cord Injury Study (RISCIS)	Drug: Riluzole Drug: Placebo	Phase 2 Phase 3	NCT01597518
A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries	Drug: Cethrin	Phase 1 Phase 2	NCT00500812
Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP)	Drug: Erythropoietin Drug: Methylprednisolone	Phase 3	NCT00561067
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI	Drug: ATI355	Phase 1	NCT00406016
Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury	Drug: Dalfampridine Drug: Placebo	Phase 2	NCT01621113

Table 2

Summary of clinical trials employing cell-based, and tissue engineering approaches

TITLE	INTERVENTIONS	PHASE	ID
Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI	Biological: Autologous Human Schwann cells	Phase 1	NCT01739023
The Safety of ahSC in Chronic SCI With Rehabilitation	Biological: Autologous Human Schwann cells	Phase 1	NCT02354625
Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury	Procedure: Autologous Adipose Tissue Derived MSCs Transplantation	Phase 1/Phase 2	NCT01769872
Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.	Other: Autologous Adipose Derived Mesenchymal Stem Cells	Phase 1	NCT01274975
Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment	Device: Laminectomy Device: Intradural space Device: Intrathecal Device: Intravenous	Phase 1/Phase 2	NCT02034669
Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury	Drug: Autologous Adipose Tissue Derived Mesenchymal Stem Cells	Phase 1	NCT01624779
Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.	Biological: Autologous Bone Marrow Cells	Phase 1 Phase 2/	NCT02260713
Cell Transplant in Spinal Cord Injury Patients	Procedure: Autologous Bone Marrow Transplant Procedure: Physical Therapy	Phase 1 Phase 2	NCT00816803
Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients	Procedure: Autologous Mesenchymal Stem Cells	Phase 2	NCT01694927
Evaluation of Autologous Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury: a Pilot Study	Other: Mesenchymal Stem Cell Transplantation	Phase 1 Phase 2	NCT02152657
Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Spinal Cord Injury	Biological: Transplantation of Autologous Stem Cell [MNCs].	Phase 1 Phase 2	NCT01833975
Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury	Biological: Bone Marrow Derived Mesenchymal Stem Cells	Phase 1 Phase 2	NCT01446640
Subarachnoid Administration of Adult Autologous Bone Marrow Mesenchymal Cells Expanded in Incomplete (SCI)	Biological: Adult autologous Mesenchymal Bone Marrow Cell	Phase 1	NCT02165904
Stem Cell Therapy in Spinal Cord Injury	Biological: Autologous Bone Marrow Mononuclear Cell Transplantation	Phase 2	NCT02009124
Safety and Efficacy of Stem Cell Therapy in Spinal Cord Injury	Biological: Autologous Bone Marrow Mononuclear Cell Transplantation	Phase 1	NCT02027246
Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury	Procedure: Stem Cell Transplantation	Phase 1	NCT01325103
Safety and Efficacy of Autologous Bone Marrow Stem Cells in Treating Spinal Cord Injury	Procedure: Laminectomy Procedure: Intrathecal	Phase 1/Phase 2	NCT01186679
To Study the Safety and Efficacy of autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury	Other: Bone Marrow Derived Stem Cells	Phase 1/Phase 2	NCT01730183
Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia	Other: Cells.	Phase 1	NCT01909154
Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury	Procedure: Mesenchymal Stem Cell Transplantation	Phase 2/Phase 3	NCT01676441
Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury	Procedure: Olfactory Mucosa Ensheathing Cell Grafting, Rehabilitation Other: Rehabilitation	Phase 1	NCT01231893

TITLE	INTERVENTIONS	PHASE	ID
Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury	Drug: HuCNS-SC cells	Phase 2	NCT02163876
Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury	Biological: Autologous Stem cell Transplantation	Phase 1/Phase 2	NCT02326662
Long-Term Follow-Up of Transplanted Human Central Nervous System stem cells (HuCNS- SC) in Spinal Cord Trauma Subjects	Other: Observation		NCT01725880
Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI	Device: Human Spinal Cord Stem Cells.	Phase 1	NCT01772810
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury	Biological: HuCNS-SC cells	Phase 1/Phase 2	NCT01321333
Nerve Regeneration-Guided Collagen Scaffold and Mesenchymal Stem Cells Transplantation in Spinal Cord Injury Patients	Device: Collagen Scaffold with Stem Cells	Phase 1	NCT02352077
Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China	Procedure: Rehabilitation of Limb Function Procedure: Stem Cells Transplantation	Phase 2	NCT01393977
Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury	Procedure: Conventional Treatment Drug: Lithium Carbonate Tablet Biological: cord blood cell Other: Placebo	Phase 1/Phase 2	NCT01471613
Different Efficacy Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With SCI in China	Procedure: Cell Therapy Other: Rehabilitation	Phase 3	NCT01873547
Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord	Biological: Umbilical cord Blood Mononuclear Cell Drug: Methylprednisolone Drug: Lithium	Phase 1/Phase 2	NCT01046786
Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury	Biological: Umbilical cord blood Mononuclear cell Biological: Methylprednisolone Drug: Lithium Carbonate Tablet	Phase 1/Phase 2	NCT01354483
Safety and Feasibility Study of Cell Therapy in Cord Tissue-Derived Treatment of Spinal Cord Injury	Biological: Intravenous and Intrathecal Human Umbilical Mesenchymal Stem Cells and Bone Marrow Mononuclear Cells	Phase 1/Phase 2	NCT02237547

Table 3

Considerations for pre-clinical study design and development

Parameters/Characteristics/Criteria for study design and to evaluate treatment efficacy	Considerations to be taken into account
Use of multiple animal models	Treatment should be tested in more than one animal
Use of different injury models	Treatment should be tested on different types of spinal cord injuries, e.g. cervical, contusion, clip compression etc.
Window of treatment	Treatment should remain efficacious with delayed administration, e.g. 1h, 3h, 6h post-SCI
Clinically meaningful efficacy	Treatment should be able to demonstrate significant, obvious improvements in locomotion, behavioral and non-behavioral aspects
Dose-response effect of therapy	Treatment doses should be realistically translatable when used in humans and efficacy should be dose- dependent
Pharmacokinetics of therapy	Mechanistic understanding of the treatment (pharmacokinetics/pharmacodynamics) should be determined, e.g. stability, release profile, metabolism changes
Overcoming drug resistance	Ensure that the spinal cord has not developed resistance to the drug therapy